Last update 01 Jul 2024

Dapagliflozin

Last update 01 Jul 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Dapagliflozin propandiol monohydrate, Dapagliflozin propanediol (USAN)

+ [22]

Target

SGLT2

Mechanism

SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)

Therapeutic Areas

Immune System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [5]

Active Indication

Diabetes Mellitus, Type 1Chronic heart failureChronic Kidney Diseases+ [9]

Inactive Indication

Diabetes Mellitus, Noninsulin-Dependent, 2Heart failure with normal ejection fractionHeart failure with reduced ejection fraction+ [14]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

Yale University

AstraZeneca PLC

+ [5]

Inactive Organization

AstraZeneca Pharmaceuticals LP

Drug Highest PhaseApproved

First Approval Date

AU (22 Oct 2012),

Chronic Kidney DiseasesDiabetes Mellitus, Type 2Heart Failure

RegulationBreakthrough Therapy (US), Fast Track (US), Priority Review (CN), Priority Review (AU)

Structure

Molecular FormulaC24H35ClO9

InChIKeyGOADIQFWSVMMRJ-UPGAGZFNSA-N

CAS Registry960404-48-2

722

Clinical Trials associated with Dapagliflozin

NCT04818034 / RecruitingPhase 2IIT

The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study

Cystinuria is an inherited autosomal recessive disorder of the kidney that is the result of an inability to reabsorb cystine from the urine. Supersaturation of cystine in the urine produces crystals that precipitate and form stones in the kidney, which can be a cause of obstruction, infection, and chronic kidney disease. Cystine stones constitute a major health challenge for affected individuals with cystinuria because of the frequent recurrence of painful symptoms and the current absence of effective, patient-accepting treatment.
A mainstay of therapy is breaking or preventing the cystine bond on the molecular level such that cystine (which is formed from the joining of two cysteine amino acids and their corresponding sulfur atoms) cannot precipitate in the urine. It is hypothesized that a glucose molecule may be able to do this if introduced into the urine. SGLT-2 inhibitors are a class of drug that are FDA approved to treat diabetes mellitus (DM) and heart failure by inhibiting an enzyme in the kidney that allows for reabsorption of glucose from the urine. This effectively increases the concentration of glucose in the urine. Our hypothesis suggests that administration of this drug to patients with cystine will introduce sufficient glucose into the urine to prevent the formation of cystine stones. To date, there has been no published data on the effectiveness of this therapy for this indication, although the dosage and administration would be identical to that already approved by the FDA for the treatment of DM and heart failure.

Start Date02 May 2025

Sponsor / Collaborator

The University of California, San Francisco

TCTR20240524007 / Not yet recruitingPhase 1

A randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence bioequivalence study of Dapagliflozin Tablet 10 mg relative to Originator FORXIGA (Dapagliflozin) tablets 10 mg in healthy Thai volunteers under fasting condition

Start Date12 Nov 2024

Sponsor / Collaborator-

NCT06405178 / Not yet recruitingPhase 3IIT

Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation in Women With Polycystic Ovarian Syndrome

The aim of the study is to assess the efficacy of adjuvant therapy dapagliflozin, metformin as monotherapy and combination of both in comparison to control group in induction of ovulation with letrozole in women PCOS, focusing specifically on rates of ovulation and pregnancy.

Start Date30 Sep 2024

Sponsor / Collaborator

Beni-Suef University

100 Clinical Results associated with Dapagliflozin

100 Translational Medicine associated with Dapagliflozin

100 Patents (Medical) associated with Dapagliflozin

2,616

Literatures (Medical) associated with Dapagliflozin

01 Mar 2024·European journal of pharmacology

Investigation of co-treatment multi-targeting approaches in breast cancer cell lines

Article

Author: Battastini, Ana Maria Oliveira ; Scholl, Juliete Nathali ; Dias, Camila Kehl ; Longaray, Jéssica Brzoskowski ; Figueiró, Fabrício

In 2020, breast cancer (BC) has surpassed lung cancer as the most diagnosed cancer in the world. Tumor microenvironment (TME) plays a critical role in resistance to standard therapies and tumor progression. Two key factors within the TME include adenosine, an immunosuppressive molecule, and glucose, which serves as the primary energy source for tumor cells. In this scenario, inhibiting the purinergic pathway and glucose uptake might be a promising strategy. Therefore, we sought to evaluated different treatment approaches in BC cells (Dapagliflozin, a SGLT2 inhibitor; Paclitaxel, the standard chemotherapy for BC; and ARL67156/APCP, inhibitors of CD39 and CD73, respectively). The expression of some membrane markers relevant to resistance was assessed. BC cell-lines (MCF-7 and MDA-MB-231) were co-treated and cell viability, cell cycle, and annexin/PI assays were performed. Our analysis showed promising results, where the combination of these compounds led to cell death by apoptosis/necrosis and cell cycle arrest. Dapagliflozin showed more impact on early apoptosis, whereas Paclitaxel led to late apoptosis/necrosis as the main mechanism of cell death. Inhibiting purinergic signaling also contributed to reducing cell viability together with the other drugs, suggesting it could have an influence on breast cancer survival mechanisms. Indeed, the overexpression of the NT5E gene in patients with ER+ tumors is strongly associated with reduced overall survival and progression-free interval. However, more studies are needed to fully understand the interactions and mechanism underlying these co-treatment multi-targeting approaches.

01 Mar 2024·Journal of pharmaceutical and biomedical analysis

Bariatric surgery and changes in metformin distribution: About a fatal case

Article

Author: Feisthauer, E ; Kintz, P ; Blanchot, A ; Gheddar, L ; Raul, J S ; Arbouche, N ; Ameline, A

A 65 year-old woman, suffering from mellitus type 2 diabetes and obesity, died at home, three days after bariatric surgery (Roux-en-Y gastric by-pass: RYGB). Her treatment, including metformin and dapagliflozin, was stopped before surgery and not postoperatively reinstalled. A forensic autopsy, toxicological and histological analyses were performed. No macroscopic or microscopic evidence of digestive perforation or peritonitis was identified, excluding an early surgery complication as the cause of death. Toxicological analysis revealed the presence of Metformin in all matrices tested, with a potentially fatal blood concentration. Death was attributed to lactic acidosis caused by a metformin overdose. With no evidence for suicide by ingestion of metformin, the authors supposed that the bariatric surgery might have caused changes in the absorption of metformin, leading to a rapid overdose and death. The only study in the literature on this subject, demonstrated a significant increase in the bioavailability of metformin following oral administration in gastric bypass patients. Thus, it can be anticipated that a therapeutic dose can become toxic when administrated to a subject who recently modified her digestive equipment. As this represents the first case of metformin overdose following bariatric surgery, further cases will be needed to confirm our initial observations.

28 Feb 2024·Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial

Article

Author: Mercier, Anne-Kristina ; Wijkmark, Emma ; Ambery, Philip ; Althage, Magnus ; Heerspink, Hiddo J L ; Dwyer, Jamie P ; Sunnåker, Mikael ; Law, Gordon ; Turton, Michelle ; Ahlström, Christine ; Greasley, Peter J ; Wheeler, David C ; Lin, Min

ABSTRACT:

Background:

Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are part of the standard of care for patients with chronic kidney disease (CKD), both with and without type 2 diabetes. Endothelin A (ETA) receptor antagonists have also been shown to slow progression of CKD. Differing mechanisms of action of SGLT2 and ETA receptor antagonists may enhance efficacy. We outline a study to evaluate the effect of combination zibotentan/dapagliflozin versus dapagliflozin alone on albuminuria and estimated glomerular filtration rate (eGFR).

Methods:

We are conducting a double-blind, active-controlled, Phase 2b study to evaluate the efficacy and safety of ETA receptor antagonist zibotentan and SGLT2i dapagliflozin in a planned 415 adults with CKD (Zibotentan and Dapagliflozin for the Treatment of CKD; ZENITH-CKD). Participants are being randomized (1:2:2) to zibotentan 0.25 mg/dapagliflozin 10 mg once daily (QD), zibotentan 1.5 mg/dapagliflozin 10 mg QD and dapagliflozin 10 mg QD alone, for 12 weeks followed by a 2-week off-treatment wash-out period. The primary endpoint is the change in log-transformed urinary albumin-to-creatinine ratio (UACR) from baseline to Week 12. Other outcomes include change in blood pressure from baseline to Week 12 and change in eGFR the study. The incidence of adverse events will be monitored. Study protocol–defined events of special interest include changes in fluid-related measures (weight gain or B-type natriuretic peptide).

Results:

A total of 447 patients were randomized and received treatment in placebo/dapagliflozin (n = 177), zibotentan 0.25 mg/dapagliflozin (n = 91) and zibotentan 1.5 mg/dapagliflozin (n = 179). The mean age was 62.8 years, 30.9% were female and 68.2% were white. At baseline, the mean eGFR of the enrolled population was 46.7 mL/min/1.73 m2 and the geometric mean UACR was 538.3 mg/g.

Conclusion:

This study evaluates the UACR-lowering efficacy and safety of zibotentan with dapagliflozin as a potential new treatment for CKD. The study will provide information about an effective and safe zibotentan dose to be further investigated in a Phase 3 clinical outcome trial.

Clinical Trial Registration Number:

NCT04724837

181

News (Medical) associated with Dapagliflozin

26 Jun 2024

·www.fiercepharma.com

New CKD drugs are promising, but need stronger efficacy data, kidney docs say: GlobalData

In total, the chronic kidney disease market is forecast to balloon in size from $2.2 billion last year to $13.5 billion by 2033, during which time a range of new treatments are on track to make their debuts. Though a host of drugs currently under development are poised to massively expand the existing market for chronic kidney disease (CKD) treatments, they’ll need to go further to win the support of doctors, according to a new report. The segment is expected to expand at a compound annual growth rate of nearly 20% over the course of a decade, according to GlobalData’s estimates. The report comprises the seven major markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan, though GlobalData noted that the U.S. will be a disproportionately large contributor to that growth, thanks to its higher prevalence of CKD and costs of prescription medications. In total, the CKD market is forecast to balloon in size from $2.2 billion last year to $13.5 billion by 2033, during which time a range of new treatments are on track to make their debuts. Among those now in development are ProKidney’s cell therapy rilparencel, also known as React, and AstraZeneca’s combinations of zibotentan and dapagliflozin, and balcinrenone and dapagliflozin—all of which are currently in clinical trials. Meanwhile, Novo Nordisk is also exploring a potential expanded indication for Ozempic in CKD. Just last month, Novo shared results from its FLOW study of once-weekly Ozempic’s ability to reduce the risk of major kidney disease events in patients with both CKD and Type 2 diabetes. With a median follow-up period of nearly three and a half years, the study found that participants treated with the GLP-1 had an average 24% risk reduction compared to those assigned to the placebo group, and their rate of kidney function decline was “significantly slower.” Additionally, semaglutide was shown to reduce the risk of major cardiovascular events by 18% and all-cause mortality by 20%. Following that data drop, Novo confirmed that it will pursue expanded approvals for Ozempic in the U.S. and Europe by the end of this year. Despite the promising results from the studies of those and other potential new CKD therapeutics so far, according to GlobalData, many kidney doctors have yet to be convinced to shake up their existing CKD treatment standards and have “mixed views” about tacking on another drug to their patients’ current regimens. “It will be easier for new drug entrants to capture CKD market share if they offer a novel mechanism of action or help to improve compliance,” Kajal Jaddoo, senior pharma analyst at GlobalData, said in the report. “Overall, nephrologists surveyed by GlobalData have indicated that the pipeline for CKD is somewhat promising, but a significant improvement in efficacy would have to be demonstrated by any therapy for it to become either a replacement or add-on to the existing therapies.”

Clinical ResultDrug ApprovalCell Therapy

24 Jun 2024

·www.prnewswire.com

Common Type 2 Diabetes Drug Shown to Safely Reduce the Progression of Kidney Disease in Adolescents with Type 1 Diabetes

SGLT2i Shown as Potential Solution to Help Manage Renal Complications and Improve Glycemic Control for Young Individuals Living with Type 1 Diabetes ORLANDO, Fla., June 24, 2024 /PRNewswire/ -- Today, findings from the ATTEMPT study, showed that a low-dose of SGLT2 inhibitor could safely be given to youth and adolescents with type 1 diabetes to improve kidney function and glycemic management. ATTEMPT is the first of its kind, landmark trial designed to evaluate the effectiveness of SGLT2 inhibitors to optimize diabetes control and prevent early subclinical kidney complications in an at-risk pediatric population with type 1 diabetes. The results were presented as a Late-Breaking Symposium at the 84th Scientific Sessions of the American Diabetes Association® (ADA) in Orlando, FL. Type 1 diabetes impacts 352,000 children and adolescents younger than an age of 20 years. Diabetes is the number one cause of kidney disease, highlighting the need for renal precautions and interventions among individuals with diabetes. About 65% of children with type 1 diabetes may experience kidney complications which can lead to chronic kidney disease (CKD) as they age. ATTEMPT (The Adolescent Type 1 Diabetes Treatment with SGLT2i for hyperglycEMia & hyperfiltration Trial) is a double-blinded, randomized, placebo-controlled trial that evaluated the impact of the SGLT2 inhibitor, Dapagliflozin, versus a placebo in combination with insulin therapy in adolescents with type 1 diabetes. Over a 16-week monitoring period, this trial assessed detailed renal mechanistic evaluations with direct measurement of glomerular filtration rate (GFR), glycemic control (HbA1c), and safety outcomes in 98 participants with type 1 diabetes. As a result, the ATTEMPT trial provides essential information in establishing a framework for young adolescents to evaluate key physiologic, mechanistic, and metabolic outcomes when using SGLT2i alongside insulin in type 1 diabetes. The study demonstrated that a low dose of SGLT2 inhibitor could safely be given to youths and adolescents to improve kidney function as well as improve glycemic management. Treatment with low dose Dapagliflozin attenuated direct measures of GFR and was associated with a significant decline in HbA1c of 0.48% (P=0.001). No significant differences in the proportion of participants who experienced adverse events, elevated ketone levels, hypoglycemia and genitourinary tract infections in the Dapagliflozin vs Placebo groups were seen. A single case (N=1) of mild DKA was seen in the Dapagliflozin group. While rates of DKA were low, a greater number of elevated blood ketone events ≥0.6mmol/L were seen in the Dapagliflozin group (n=106) vs Placebo group (n=62) (P<0.001), emphasizing the patient centered DKA Risk Mitigation Education strategy operationalized during the study. "This study paves the way for us to evaluate treatments that can reduce kidney disease progression for those with type 1 diabetes," said Farid Mahmud, MD, University of Toronto, lead investigator of study. "These findings also give us meaningful insights as we look how we optimize diabetes management in youth and young adults during a challenging period associated with kidney disease progression and above-target A1c." The authors note the trial was designed with protocols to successfully mitigate the risk for diabetic ketoacidosis, a risk that will need to be considered before these drugs can be widely used in clinical practice. They also state that the ATTEMPT Trial paves the way for researchers to produce longer studies that could help better understand additional benefits of adjunctive therapy in type 1 diabetes. The ATTEMPT Study was supported by JDRF Canada in partnership with the Canadian Institute of Health Research (CIHR), Strategies for Patient Oriented Research (SPOR). Research presentation details: Dr. Mahmud will present the findings at the following symposium: Late- Breaking Symposium: Use of SGLT2i in Youth with Type 1 Diabetes—Results from ATTEMPT (The Adolescent Type 1 Diabetes Treatment with SGLT2i for hyperglycEMia & hyPerfilTration Trial) Session: Monday, June 24, 2024 at 3:15 – 4:15 PM ET About the ADA's Scientific Sessions The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions. About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life®. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn). Contact: Amy Robinson [email protected] SOURCE American Diabetes Association

Clinical ResultClinical Study

19 Jun 2024

·www.prnewswire.com

Daewoong Presents Enavogliflozin's Phase 3 Pooled Analysis Results at 84th ADA Conference

ORLANDO, Fla., June 19, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (CEOs Chang-jae Lee and Seongsoo Park) announced that it will present the pooled analysis results of the Phase 3 clinical trials for Enavogliflozin at the 84th American Diabetes Association conference in Orlando, USA, from June 21 to 24. These results showcase Enavogliflozin's efficacy and safety in patients with mild renal impairment who struggle with blood glucose control. Professor Lyu Young-sang from the Endocrinology and Metabolism Department at Chosun University Hospital will present the study, which includes the pooled analysis results of the Phase 3 clinical trial of Enavogliflozin combined with metformin. The findings highlight Enavogliflozin's superior blood glucose-lowering effects compared to dapagliflozin in type 2 diabetes patients with mild renal impairment. The presentation will cover Enavogliflozin's enhanced blood glucose control, increased urinary glucose excretion, and improved insulin resistance. The study shows Enavogliflozin's superior blood glucose-lowering effects compared to dapagliflozin, with a significant reduction in glycated hemoglobin (HbA1c) levels. Over 24 weeks, Enavogliflozin reduced HbA1c by 0.94%, compared to 0.77% with dapagliflozin. Additional benefits include reduced fasting plasma glucose levels, increased urinary glucose excretion, and improved insulin resistance. The ADA conference will attract over 12,000 professionals worldwide. Enavogliflozin, Korea's first SGLT-2 inhibitor developed by Daewoong, will be recognized for its innovation and effectiveness. CEO Chang-jae Lee stated, "Enavogliflozin is gaining attention as a potential replacement for dapagliflozin. This presentation will showcase its excellence to healthcare professionals globally." Enavogliflozin stands out for its superior HbA1c reduction at a low dosage of 0.3mg, a high target blood glucose achievement rate (HbA1c < 7%) of approximately 70%, improvement in cardiovascular risk factors, and extensive clinical data on Korean patients. Forward-Looking Statements This press release contains forward-looking statements that are based on the current beliefs and expectations of Daewoong Pharmaceutical's management. Factors that could cause or contribute to such differences include, but are not limited to: (1) Regulatory and governmental approvals: The approval process for pharmaceutical products is subject to extensive regulations and may involve uncertainties and delays. Any failure to obtain necessary approvals or the occurrence of delays in the approval process could adversely affect Daewoong Pharmaceutical's business and results of operations; and (2) Clinical trials: The success of Daewoong Pharmaceutical's products depends on the results of clinical trials. The results of early clinical trials may not be indicative of the results of later-stage or larger-scale clinical trials. SOURCE Daewoong Pharmaceutical Co., Ltd.

Phase 3

100 Deals associated with Dapagliflozin

External Link

KEGG	Wiki	ATC	Drug Bank
D09763	Dapagliflozin	A10BK01	DB06292

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	JP	AstraZeneca Pharmaceuticals Co., Ltd.	26 Mar 2019
Chronic heart failure	EU	AstraZeneca AB	11 Nov 2012
Chronic heart failure	IS	AstraZeneca AB	11 Nov 2012
Chronic heart failure	LI	AstraZeneca AB	11 Nov 2012
Chronic heart failure	NO	AstraZeneca AB	11 Nov 2012
Chronic Kidney Diseases	AU	AstraZeneca Pty Ltd.	22 Oct 2012
Diabetes Mellitus, Type 2	AU	AstraZeneca Pty Ltd.	22 Oct 2012
Heart Failure	AU	AstraZeneca Pty Ltd.	22 Oct 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute myocardial infarction	Phase 3	SE	AstraZeneca PLC	22 Dec 2020
Acute myocardial infarction	Phase 3	GB	AstraZeneca PLC	22 Dec 2020
Diabetes Mellitus	Phase 3	SE	AstraZeneca PLC	22 Dec 2020
Diabetes Mellitus	Phase 3	GB	AstraZeneca PLC	22 Dec 2020
Heart failure with reduced ejection fraction	Phase 3	US	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	JP	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	BR	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	CA	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	DK	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	SK	AstraZeneca PLC	09 Apr 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03801642 (CTgov)	Phase 1/2	Alzheimer Disease	46	Dapagliflozin (Dapagliflozin)	kyfrwhtrkd(ozvdmgcstt) = zcifpdiqyn qchfwvskqz (eudlsdrkoi, wxbgfcgnlp - yghgzdzvys) View more	-	13 Jun 2024
				Placebo (Matching Placebo)	kyfrwhtrkd(ozvdmgcstt) = dwdwtfhxeb qchfwvskqz (eudlsdrkoi, evpvmutdvv - hjskfquatx) View more
NCT04298229 (DICTATE-AHF, Pubmed)	Phase 3	Diabetes Mellitus, Type 2 \| Heart Failure	240	Dapagliflozin 10 mg once daily	npznwggsnx(tgpoxsjqvk): OR = 0.65 (95% CI, 0.41 - 1.02), P-Value = 0.06	Positive	09 Apr 2024
				Dapagliflozin
NCT03782259 (Pubmed)	Phase 4	Diabetes Mellitus, Type 2 IL-1B \| TNFα \| IL-6 ... View more	62	Dapagliflozin 10 mg	gbapcelayz(tzvciccbjn) = dxourpglfo wbfjnvoeba (bfcrtrahwh )	-	25 Mar 2024
NCT04298229 (DICTATE-AHF, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Heart Failure	240	diuretic (Structured Usual Care)	bhhsvotkvj(yxoyrncdss) = ebghznadkg xyppmetcsf (vapsvqihkx, qwblozcpua - cifztmevkg) View more	-	15 Mar 2024
				Dapagliflozin (Dapagliflozin Plus Structured Usual Care)	bhhsvotkvj(yxoyrncdss) = svojgqebzr xyppmetcsf (vapsvqihkx, zorfisiwhh - dornoedxan)
NCT02777073 (CTgov)	Not Applicable	Diabetes Mellitus, Type 1 \| Hyperglycemia	43	Victoza (Liraglutide 1.8 mg)	ijabnlzrgm(fnayifzfzb) = usjluhyuwf kmjpcbhqja (sdrblpmaqi, skxfldmemy - zzkzazjqom) View more	-	29 Feb 2024
				Placebo (Placebo)	ijabnlzrgm(fnayifzfzb) = wsrujjayvl kmjpcbhqja (sdrblpmaqi, welgsnqohy - dbosmkovcb) View more
NCT02962492 (CTgov)	Not Applicable	Diabetes Mellitus, Type 1	70	Placebo (Placebo Arm:)	xvivvqwekb(qmpfjbcfup) = mdftoilqhn onljfizikm (ixfszlavlq, dxwqcdficu - fjdztrchki) View more	-	29 Feb 2024
				Dapagliflozin (Dapagliflozin Arm:)	xvivvqwekb(qmpfjbcfup) = wkxxixdqkf onljfizikm (ixfszlavlq, skekpvkkhu - swvnoywfho) View more
NCT03619213 (DELIVER, Pubmed)	Phase 3	Heart failure with reduced ejection fraction natriuretic peptides	1,151	Dapagliflozin	hhonnbxqum(nibvionkzh): hazard ratio = 0.38 (95% CI, 0.18 - 0.79)	Positive	24 Jan 2024
				Placebo
NCT02518945 (CTgov)	Phase 3	Diabetes Mellitus, Type 1	26	Insulin+Liraglutide (Placebo)	bfoyrflihd(gueatpfmcs) = unpsycqydb sdmonftjmv (qerfociryk, eifxdcxskt - rmyuklidck) View more	-	24 Jan 2024
				Insulin+Liraglutide+Dapagliflozin (Active Drugs)	bfoyrflihd(gueatpfmcs) = gdqvtqwqas sdmonftjmv (qerfociryk, rofyjtsjtp - dntiqatrfy) View more
NCT04401904 (CTgov)	Phase 1/2	Prediabetic State \| Obesity	20	Dapagliflozin 10 mg (Dapagliflozin)	xwbqnslqkf(zqofbxjjcl) = xckplzbfib uzxjoytxvp (tmjspihifg, cxabkipnhe - mprrbfirtb) View more	-	05 Jan 2024
				Nutritional counseling (Nutritional Counseling)	xwbqnslqkf(zqofbxjjcl) = jxteaolkbf uzxjoytxvp (tmjspihifg, ovtywoinvs - foacpzqgvr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis